Impact
Research discoveries drive progress against prostate cancer, and the good news is that between 1994 and 2019, the death rate from prostate cancer has dropped by half.
Our first research grant in 1996 was essential for the development of active surveillance, an approach that monitors low risk prostate cancer and only offers treatment to patients when their disease progresses. This approach is now the international standard for early stage cancer – saving millions of men from unnecessary treatment.
The research we fund looks into prevention, early and better diagnosis, improved treatments and better quality of life for survivors.
Since 1994, in partnership with Movember Foundation, we have invested $120 million in leading Canadian research that gives hope to those affected. Annually, we invest an average of $50 million into 60+ new and ongoing projects. We support the work of more than 200 researchers at 50 universities and hospitals in nine provinces.
The new knowledge we help generate in Canada is making a difference in the lives of those affected by prostate cancer.